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BACKGROUND: Receipt of chemotherapy at the end of life (EOL) is considered an indicator of poor quality of care for medical oncol-
ogy. The objective of this study was to characterize the use of radiotherapy (RT) in patients with nonsmall cell lung cancer (NSCLC)
during the same period. METHODS: Treatment characteristics of patients with incurable NSCLC who received RT at the EOL, defined
as within 14 days of death, were analyzed from the National Comprehensive Cancer Network NSCLC Outcomes Database. RESULTS:
Among 1098 patients who died, 10% had received EOL RT. Patients who did and did not receive EOL RT were similar in terms of sex,
race, comorbid disease, and Eastern Cooperative Oncology Group performance status. On multivariable logistic regression analysis,
independent predictors of receiving EOL RT included stage IV disease (odds ratio [OR], 2.04; 95% confidence interval [CI], 1.09-3.83)
or multiorgan involvement (OR, 1.75; 95% CI, 1.08-2.84) at diagnosis, age <65 years at diagnosis (OR, 1.85; 95% CI, 1.21-2.83), and treat-
ing institution (OR, 1.24-5.94; P ¼ .02). Nearly 50% of EOL RT recipients did not complete it, most commonly because of death or
patient preference. CONCLUSIONS: In general, EOL RT was received infrequently, was delivered more commonly to younger patients
with more advanced disease, and often was not completed as planned. There also was considerable variation in its use among
National Comprehensive Cancer Network institutions. Next steps include expanding this research to other cancers and settings and
investigating the clinical benefit of such treatment. Cancer 2012;118:4339-45.VC 2012 American Cancer Society.
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INTRODUCTION
Nonsmall cell lung cancer (NSCLC) remains the most commonly diagnosed malignancy in the United States, and an esti-
mated 200,000 Americans received this diagnosis in 2010.1 Although advances in diagnosis and treatment have improved
cancer-related mortality, most patients will die of progressive disease. Generally speaking, approximately half of all
patients with NSCLC eventually will receive radiotherapy (RT) for either local disease or metastatic disease.2 A previous
Surveillance, Epidemiology, and End Results (SEER)-Medicare database analysis noted that 58% of patients who were
diagnosed with metastatic NSCLC received some form of palliative RT.3 However, there are no data on the frequency
with which RT is given at the end of life (EOL).
The receipt of EOL chemotherapy has been examined previously by several investigators. Earle and his colleagues
identified a cohort of patients in a SEER-Medicare data set and characterized the frequency of chemotherapy administered
during the last 14 days of life. Receipt of chemotherapy in this time frame by>10% of patients was correlated significantly
with higher rates of aggressive EOL care (eg, more frequent emergency room visits, intensive care unit/hospital admis-
sions, and hospital deaths and less use of hospice and advanced care directives).4 This ‘‘10% rule’’ has been validated at
other institutions, confirming the finding that late chemotherapy administration is a barometer of health care over-use.5
In contrast, little is known regarding the frequency with which RT is delivered at the EOL. The primary objectives
of this report were to determine the rate of use of RT near the EOL among patients with NSCLC and to identify the fac-
tors associated with such use. A secondary aim was to characterize the technical aspects of the RT received.
MATERIALS AND METHODS
Patients
The study cohort consisted of patients who were evaluated at 1 of 8 National Comprehensive Cancer Network (NCCN)
member institutions participating in the NCCN NSCLC Outcomes Database Project between January 2007 and March
2010. Institutions included City of Hope Comprehensive Cancer Center, Dana-Farber Cancer Institute, Duke Cancer
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Institute, The Sidney Kimmel Comprehensive Cancer
Center at JohnsHopkins, The Ohio State University Com-
prehensive Cancer Center, Roswell Park Cancer Institute,
University of Michigan Comprehensive Cancer Center
and The University of Texas MD Anderson Cancer Cen-
ter. Patients were excluded from the analysis if they were
previously diagnosed with NSCLC within 2 years or with
any invasive malignancy within 5 years. Patients who pre-
sented for a second opinion were not eligible for inclusion
in the database. An institutional review board at each center
approved of the data collection, storage, and analysis for
this project. For institutions that required patient informed
consent, data collection was limited to patients who had
provided consent.
Data Collection/Data Sources
Patient data were collected longitudinally through a medical
record chart review by trained abstractors at each institution.
Baseline information is abstracted 6 months after presenta-
tion with a pathologically confirmed diagnosis of NSCLC
and is then reviewed and updated every 6 months for the
first 2 years of follow-up and annually thereafter. Baseline
characteristics include the patient’s date of birth, sex, race,
ethnicity, type of insurance, number of comorbidities, East-
ern Cooperative Oncology Group (ECOG) performance
status, tumor-lymph node-metastasis (TNM) stage, and his-
tology. Dates and locations of metastatic disease collected at
diagnosis and during follow-up also are reported along with
RT and systemic therapy data from both NCCN institu-
tions and outside institutions. Detailed RT data include
treatment sites, treatment indication, treatment type, and
number of fractions. EOL data consists of death date, cause
of death, and EOL discussion events. For the current analy-
sis, RT data were limited to therapy received after a patient’s
earliest distant metastasis diagnosis.
The Outcomes Database Project uses rigorous qual-
ity-assurance procedures to maintain a high level of accu-
racy of the data. These include real-time, web-based edit
checking; programmed logic check queries of the pooled
data repository; quality-assurance reports that are
reviewed by the data managers on a quarterly basis;
monthly data-management training calls; biannual, in-
person data-management training sessions; and on-site
audits of a random sample of source documents against
the submitted data performed within the first few months
of data entry and annually thereafter.
Definitions
Patients were defined as having received (EOL) RT if they
received RT at an NCCN institution or a non-NCCN
institution within 14 days of death. This included patients
who started or ended any form of RT within 14 days of
death. Receipt of systemic therapy within 14 days of death
was similarly defined.
Statistical Methods
Categorical variables were used to analyze age at diagnosis
(age 54 years, 55-64 years, or 65 years), insurance
type (Medicare with or without a second insurance type,
managed care alone, other), ECOG performance status
(0, fully active; 1, restricted activities; 2-4, cannot work/
fully dependent; or unknown performance status), and
NCCN institution. Binary variables were used to exam-
ine sex (men/women), race (Caucasian/other), Charlson
comorbidity index score (0/1þ), stage at diagnosis
(IV/I-III), presence of multiple metastatic sites (yes/no),
documented EOL discussion (yes/no), receipt of
EOL RT (yes/no), and receipt of EOL systemic therapy
(yes/no).
Baseline characteristics were stratified by the receipt
of EOL RT. The association between the receipt of EOL
RT and various demographic and clinical factors was
assessed with logistic regression modeling. Individual fac-
tors were modeled first to check for univariate association
with the receipt of EOL RT. Variables with a significance
level of  .2 from the univariate analyses were considered
for the final multivariable model. Multivariable logistic
regression was performed to identify the factors associated
with the receipt of EOL RT. The final significance level
was set to an a level of .05. Point estimates from the mul-
tivariable model are reported as odds ratios (ORs) with
the corresponding 95% confidence interval (CI) for each
OR. All statistical analyses were conducted using the SAS




Between January 1, 2007 and March 1, 2010, 3074
patients diagnosed with NSCLC were identified through
the Outcomes Database Project. More than half of these
(1749 patients) had stage IV or IIIB disease with a malig-
nant effusion at time of database entry or had a metastatic
recurrence. Of these, 1218 patients had a recorded death
as of March 30, 2010. Thirty patients were excluded from
further analysis because of incomplete baseline informa-
tion, and 90 patients were excluded because of a past inva-
sive cancer other than NSCLC. Therefore, the final
cohort consisted of 1098 patients. Of these, 730 patients
(66%) subsequently received RT at some point after being
diagnosed with incurable disease, and 115 of those
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patients (10%) received this treatment at the EOL (Fig.
1).
There were some significant differences between
patients who did and did not receive EOL RT (Table 1).
Patients who received EOL treatment were younger (me-
dian age, 60 years vs 64 years), were less likely to have
Medicare-related health insurance, and presented with
more advanced disease (metastatic disease at the time of
diagnosis and/or disease involving multiple organs). Oth-
erwise, both groups were similar with regard to sex, race,
comorbidity status, performance status, and documenta-
tion of EOL discussions. The rate of chemotherapy
receipt at the EOL was 10% among those patients who
received EOL RT and 11% among those who did not
receive EOL RT (P¼ .86).
Multivariable Analysis of Radiotherapy at the
End of Life:
Patients who had stage IV (or IIIB) disease at the time of
diagnosis were twice as likely to receive EOL RT as
patients who had stage I, II, or III disease (OR, 2.04; 95%
CI, 1.09-3.83) (Table 2). Furthermore, patients who were
diagnosed initially with multiple sites of metastatic disease
were 75% more likely to receive EOL RT than those who
were diagnosed initially with a single site of metastasis
(95% CI, 1.08-2.84). Younger patients (aged <65 years)
were 1.85 times as likely as older patients to receive EOL
RT (95% CI, 1.21-2.83). There also was significant inter-
institutional variation in the EOL RT rate (OR range,
1.24-5.94; P¼ .02).
Treatment Characteristics
Twenty-two percent of patients received more than 1
course of treatment at the EOL; thus, 115 patients
received 131 courses of treatment (Table 3). Of the 131
courses, 25 courses (19%) involved 3 fractions (includ-
ing 4 patients who received single-fraction stereotactic
external beam or gamma-knife brain radiosurgery), 40
courses (30%) consisted of 10 fractions, and 23 courses
(17%) involved>10 fractions (Fig. 2).
EOL RT was not completed as prescribed by 54 of
the 115 patients (47%), including 19 patients who died
during the course of treatment and 11 patients who
elected not to finish their originally prescribed course.
The remaining 24 patients discontinued treatment
because of disease progression, treatment toxicity (either
RT or chemotherapy), transfer of care, comorbid illness,
or reasons that were not reported (Fig. 3).
Commonly treated sites at the EOL included the
brain (28%), chest (27%), spine (25%), and bones other
than spine (13%). Complexity of therapy was weighted
toward 3-dimensional conformal therapy, as 42% of
RT courses used this modality (Table 4). Simpler treat-
ment techniques were used in 33% of RT courses, and
8% of courses used more technologically complex meth-
ods, such as intensity-modulated RT or stereotactic radio-
surgery. Data regarding treatment modality were not
available for 17% of courses.
DISCUSSION
For this report, we examined the frequency with which
RT was delivered to a group of patients with incurable
NSCLC at 8 NCCN institutions during their last 2 weeks
of life. Overall, 10% of these patients received radiation
treatments within that period compared with 11% for
chemotherapy. We observed that younger patients and
those with more advanced disease were statistically more
likely to receive RT at the EOL and that there was signifi-
cant variation in its use between centers. Although most
patients were prescribed a single course of therapy, nearly
half did not complete it, most commonly because of inter-
current death, disease, or patient preference.
There is growing interest in optimizing the use of
health care, especially at the EOL. EOL cancer treatment
deserves closer examination, because cancer accounts for
nearly 25% of all deaths in the United States.1 It is esti-
mated that 159,000 patients died of lung cancer alone in
Figure 1. The time from the end of radiotherapy (RT) to death
is illustrated among patients who received RT after diagnosis.
In total, 115 patients with either stage IIIB or stage IV non-
small cell lung cancer died within 14 days of receiving RT,
representing approximately 10% of the 730 patients who
received RT at any point after the diagnosis of incurable
disease.
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Table 1. Baseline Patient Characteristics Stratified by Receipt of End-of-Life Radiation Therapy (N ¼ 1098)
No. of Patients (%)
Characteristic Radiation Within 14 Days
of Death, N 5 115
No Radiation Within 14 Days
of Death, N 5 983a
P
Age at diagnosis: Median [range], (y) 60 [37-84] 64 [25-96] <.01
£54 34 (30) 249 (25)
55-64 46 (40) 285 (29)
‡65 35 (30) 449 (46)
Sex .45
Men 56 (49) 515 (52)
Women 59 (51) 468 (48)
Caucasian .30b
No 18 (16) 196 (20)
Yes 95 (83) 784 (80)
Unknown 2 (2) 3 (0)
Insurancec <.01b
Medicare-related 37 (32) 463 (47)
Managed care alone 69 (60) 384 (39)
Other 9 (8) 134 (14)
Unknown 0 (0) 2 (0)
Stage <.01
I-III 12 (10) 205 (21)
IV 103 (90) 778 (79)
NCCN institution .09
A 4 (5) 74 (95)
B 5 (6) 75 (94)
C 16 (12) 122 (88)
D 11 (13) 74 (87)
E 6 (7) 86 (93)
F 32 (10) 302 (90)
G 12 (20) 49 (80)
H 29 (13) 201 (87)
ECOG performance status .90
0: Fully active 23 (20) 215 (22)
1: Restricted activities 40 (35) 359 (37)
2-4: No work/dependent 20 (17) 156 (16)
Unknown 32 (28) 253 (26)
Charlson Comorbidity Index score .81
0 66 (57) 553 (56)
‡1 49 (43) 430 (44)
Multiple metastatic sites .01
No 26 (23) 339 (34)
Yes 89 (77) 644 (66)
Documented end-of-life discussion .34
No 56 (49) 525 (53)
Yes 59 (51) 458 (47)
Receipt of chemotherapy in last 14 d of life .86
No 103 (90) 875 (89)
Yes 12 (10) 108 (11)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NCCN, National Comprehensive Cancer Network.
a Includes patients who never received RT treatment in the metastatic setting (N ¼ 368) and those who received RT in the metastatic setting, but not during
the last two weeks of life (N ¼ 615).
b Analysis performed after excluding patients with unknown values.
cMedicare-related insurance refers to Medicare alone, Medicare plus supplemental insurance, and Medicare plus managed care. Other insurance also
includes indemnity, Medicare/indigent, and/or self-pay.
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20096 and that a considerable share of these patients’
health care expenses were incurred during the last months
of life.6-9 However, it is not clear whether more aggressive
EOL care improves either the duration or the quality of
life. For example, Temel et al observed that, for patients
with newly diagnosed metastatic NSCLC, there were stat-
istically significant survival and quality-of-life benefits
among patients who used fewer health care services.10
After accounting for confounding variables, we
observed that younger patients were more likely to receive
EOL RT, which concurs with previously reported Ameri-
can and Canadian data.7,8,11,12 Although the reasons for
this are not entirely clear, it is possible that younger
patients and/or their providers pursue more aggressive
treatment despite the finding that their survival rates are
similar to the rates among older patients who receive more
conservative treatment.13 Previous studies that aimed to
define the factors associated with palliative RT indicated
that patients with metastatic disease who have lower socio-
economic status3,7,11 and those who live in nursing homes
or rural settings are less likely to be referred for RT and,
thus, to receive less treatment.7,8,11 Unfortunately, the
NCCN database does not currently capture information
on patients’ socioeconomic status or living situation, so
we were not able to assess these factors as part of our
analysis.
We also were able to detect differences in the fre-
quency with which EOL RT was prescribed between cen-
ters. Other investigators previously noted geographic
variation in the receipt of palliative RT, citing the type of
center (academic vs freestanding)3 or variation in logistic
challenges between centers as factors that affect the likeli-
hood of being referred for or receiving palliative RT.7
Although all centers that were included in the current
report were affiliated with academic institutions, it is pos-
sible that the variation we observed may have been caused
by variation in local practice patterns or even the relative
Table 2. Factors Associated with Receipt of Radiation within
14 Days of Death in Multivariable Logistic Regression Analysis
(N ¼ 1098)a
Variable OR 95% CI P
Stage at diagnosis .03
I-III 1.00
IV 2.04 1.09-3.83

















Abbreviations: CI, confidence interval; NCCN, National Comprehensive
Cancer Network; OR, odds ratio.
a The analysis was performed after excluding patients with unknown values.











a The data exclude patients whose treatment technique was not reported or
who received single-fraction stereotactic body radiotherapy, and the num-
ber of courses is greater than the number of patients treated, because
some patients received multiple courses of radiotherapy at the end of life.
Figure 2. This chart illustrates the number of radiotherapy
fractions received per course before death. The numbers
below each bar indicate the number of fractions received as
part of the 131 courses. Included in the single-fraction data
are 4 patients (3% of courses) who underwent single-fraction
stereotactic radiosurgery. Note that the number of courses is
greater than the number of patients, because some patients
received multiple courses of treatment in the 14 days before
death. Max indicates maximum.
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ease and urgency with which patients who are referred for
palliative care are seen and treated.
With regard to the technical aspects of EOL RT, we
observed that most patients received a palliative course of
treatment that consisted of 10 fractions. Although recent
data from the United States and France suggest that this is
consistent with the standard of care,3,14,15 surveys of prac-
tice patterns elsewhere in Europe, Canada, and Australia
favor the use of single-fraction or 5-fraction regi-
mens.7,11,15 Certainly, shorter treatment courses decrease
the number of clinic visits, thereby reducing the direct
and indirect costs to the patient. From the referring physi-
cian’s perspective, the prolonged nature of palliative RT
has even been cited as a perceived barrier to care.12
It was beyond the scope of the current study to
determine whether clinical factors, routine practice pat-
terns, or other incentives explained the providers’ prefer-
ence for longer treatment regimens. Regardless, it is
important to note that abbreviated courses are most
appropriate for patients at the EOL, because several stud-
ies have demonstrated that consolidated therapy can result
in earlier andmore frequent retreatment if patients survive
longer than expected.16,17 Unfortunately, oncologists of-
ten are poor at predicting their own patients’ survival; the
accuracy of survival estimates among experienced physi-
cians only ranges between 20% and 30%, and the major-
ity of errors are over estimates.18-21 In a recent study, for
example, radiation oncologists only accurately identified
5 of 33 patients who would die within 1 month of starting
palliative RT.22 Moreover, they predicted that 7 of the 33
patients who died were going to live for at least 6 months.
Reflecting this optimism, only 61% of their patients com-
pleted treatment as prescribed, which is only slightly bet-
ter than the rate of 53% identified in the current study.
Although our data were audited for accuracy, this
report does have several limitations. First, we have com-
pared EOL RT rates with rates of chemotherapy use at the
EOL, and this may not be fair. Because RT is prescribed
for local (often acute) symptom management, whereas
chemotherapy is offered to reduce systemic disease burden
(and prolong life), it may be argued that EOL RT is a
wholly different treatment and, thus, should not be pre-
scribed in the same fashion or frequency as chemotherapy.
Second, the practice patterns at the 8 NCCN institutions
studied may not be representative of radiation oncologists
in general. Although all the centers contributing to the
database are academic research institutions, most RT in
the United States is provided in the private setting.23
Therefore, it may be inaccurate to generalize our findings
to the field as a whole. Third, we have limited this report
to patients with NSCLC. It has been demonstrated that
the rates of palliative RT differ widely, depending on
the primary disease site7,8,11; thus, if other cancers were
investigated, there could be differing rates of EOL RT.
Finally, our database did not collect detailed data on the
palliative versus curative intent of therapy, making it diffi-
cult to determine whether treatment was clinically appro-
priate. Along these lines, it would have been helpful to
know the number of planned treatments; unfortunately,
Figure 3. This chart indicates the percentage of patients who
stopped radiotherapy for various reasons. Slightly more than
half of the 115 patients who died within 14 days of receiving
radiotherapy finished their course as prescribed (indicated in
black). The remaining patients did not finish treatment for
other reasons (indicated in shades of gray).
Table 4. End-of-Life Radiotherapy Sites Treated and
Treatment Types (N ¼ 146 Courses)a
Variable No. of
Patients (%)




Bone, other than spine 19 (13)
Other 11 (8)
Treatment technique per course of RT
Conventional 2D therapy 48 (33)
3D conformal therapy 62 (42)
Intensity modulated RT 7 (5)
Stereotactic radiosurgery 4 (3)
Unknown 25 (17)
Abbreviations: 2D, 2-dimensional; 3D, 3-dimensional; IMRT, intensity-modu-
lated radiotherapy; RT, radiotherapy.
a The number of courses is greater than the number of patients treated,
because some patients received multiple courses of RT at the end of life.
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only the number of treatments received was reported as
part of the database.
In conclusion, to the best of our knowledge, this
study provides the first data on the use of EOL RT, the
factors associated with its use, and how it is delivered,
albeit at a limited number of academic centers for a single
type of cancer. It is our hope that future investigations of
this issue will be expanded to include other cancers in a
wider variety of facilities. It is also important to note that
our study does not help to define an appropriate rate of
use of RT for patients at the end of their lives. This, too, is
an important issue for future study and will be greatly
aided by having more accurate tools for predicting the life-
span of patients with metastatic disease who present for
consideration of treatment with radiation. With such in-
formation in hand, we can be more confident that our
patients not only will complete the treatments we intend
to deliver but also will achieve some durable benefit from
them. By doing so, we may come closer to answering the
key question: How often should radiation therapy be
offered at the end of life?
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